- Home
- NCTY vs AGEN Comparison
NCTY vs AGEN Comparison
Compare NCTY & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCTY
- AGEN
- Stock Information
- Founded
- NCTY 1999
- AGEN 1994
- Country
- NCTY China
- AGEN United States
- Employees
- NCTY N/A
- AGEN N/A
- Industry
- NCTY Business Services
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NCTY Consumer Discretionary
- AGEN Health Care
- Exchange
- NCTY Nasdaq
- AGEN Nasdaq
- Market Cap
- NCTY 121.2M
- AGEN 142.8M
- IPO Year
- NCTY 2004
- AGEN 2000
- Fundamental
- Price
- NCTY $10.02
- AGEN $4.55
- Analyst Decision
- NCTY
- AGEN Buy
- Analyst Count
- NCTY 0
- AGEN 2
- Target Price
- NCTY N/A
- AGEN $14.50
- AVG Volume (30 Days)
- NCTY 57.4K
- AGEN 387.3K
- Earning Date
- NCTY 01-01-0001
- AGEN 11-11-2025
- Dividend Yield
- NCTY N/A
- AGEN N/A
- EPS Growth
- NCTY N/A
- AGEN N/A
- EPS
- NCTY N/A
- AGEN N/A
- Revenue
- NCTY $15,305,175.00
- AGEN $101,706,000.00
- Revenue This Year
- NCTY N/A
- AGEN $60.49
- Revenue Next Year
- NCTY N/A
- AGEN N/A
- P/E Ratio
- NCTY N/A
- AGEN N/A
- Revenue Growth
- NCTY N/A
- AGEN N/A
- 52 Week Low
- NCTY $6.28
- AGEN $1.38
- 52 Week High
- NCTY $20.59
- AGEN $7.34
- Technical
- Relative Strength Index (RSI)
- NCTY 55.26
- AGEN 48.05
- Support Level
- NCTY $9.06
- AGEN $4.36
- Resistance Level
- NCTY $11.20
- AGEN $5.20
- Average True Range (ATR)
- NCTY 0.73
- AGEN 0.28
- MACD
- NCTY 0.13
- AGEN 0.05
- Stochastic Oscillator
- NCTY 55.13
- AGEN 40.91
About NCTY The9 Limited American Depository Shares
The9 Ltd operates a cryptocurrency mining business. It provides computing power, or hash rate, to a Bitcoin mining pool and is entitled to receive a fractional share of Bitcoin award from the Bitcoin mining pool in return. The company generates its revenues from customers in Greater China, Asia/Eastern Europe, and North America. Its segments are: Crypto mining business, and Other, out of which Crypto mining business derives maximum revenue.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).